Chimeric therapeutics, compositions, and methods for using same

1. A chimeric therapeutic comprising a modified viral core protein and a therapeutic agent, wherein the modified viral core protein is selected from the group consisting of CP155 (SEQ ID NO: 50), CP162 (SEQ ID NO: 52), and CP170 (SEQ ID NO: 54).

2. The chimeric therapeutic of claim 1 , wherein said therapeutic agent is bound to said modified viral core protein.

3. The chimeric therapeutic of claim 1 , wherein said modified viral core protein is further mutated such that at least one amino acid is independently selected from the group consisting of asparagine 21, alanine 21, valine 21, alanine 27, isoleucine 27, valine 60, and leucine 97.

4. The chimeric therapeutic of claim 3 , wherein said modified viral core protein has at least one amino acid selected from the group consisting of phenylalanine 23, aspartic acid 29, threonine 33, leucine 37, valine 120, valine 124, arginine 127, tyrosine 132, glutamic acid 77, aspartic acid 78 and alanine 80 changed to a cysteine.

5. The chimeric therapeutic of claim 1 , wherein said therapeutic agent is a nucleic acid, a protein, or a small molecule.

6. A therapeutic composition comprising:

a particle formed from a plurality of chimeric therapeutics of claim 1 , wherein said particle, optionally, further comprises a coating; and

a pharmaceutically acceptable excipient,

wherein said particle comprises 180 or 240 viral core proteins.

7. The therapeutic composition of claim 6 , wherein the particle is a modified icosahedral.

8. The therapeutic composition of claim 6 , wherein the coating comprises one or more lipid molecules.